MPN
Myelofibrosis and Bone Marrow Transplant – Mayo Clinic
Ruben Mesa, MD and Veena Fauble, MD, Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Seven Top Hematologists Help Patients Fight Rare Leukemia In A New, Free, Online Service
There’s a leukemia so rare – about five cases per one million persons – that chancesare you never heard of it or met anyone suffering from it. Most family doctors and even many hematologists have never seen a case. To help serve this patient population, seven… Continue reading
CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.)
CYT387 is a potent, selective, oral JAK1/2 inhibitor targeting the treatment of disorders such as myeloproliferative neoplasms (MPNs), cancer and inflammatory conditions. CYT387 is designed to suppress the over-activity of the JAK1 and JAK2 enzymes, including the JAK2V617F mutant. The molecule possesses an excellent selectivity and safety profile with minimal… Continue reading
CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.)
CYT387 is a potent, selective, oral JAK1/2 inhibitor targeting the treatment of disorders such as myeloproliferative neoplasms (MPNs), cancer and inflammatory conditions. CYT387 is designed to suppress the over-activity of the JAK1 and JAK2 enzymes, including the JAK2V617F mutant. The molecule possesses an excellent selectivity and safety profile with minimal… Continue reading